Skip to main content
SpringerLink
Log in

Development of a Radiolabeled Monoclonal Antibody to Prostate-Specific Membrane Antigen

  • Chapter
The Oncogenomics Handbook

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 976 Accesses

Abstract

Despite advances in the diagnosis and therapy of prostate carcinoma, it remains a serious medical problem accounting for a large number of malignancies in men each year. Although earlier detection is now possible, many patients develop advanced metastatic disease even when there is no evidence of spread at the time of initial diagnosis and treatment. These metastatic sites could initially be controlled by hormonal therapy but ultimately become resistant and the disease enters an aggressive stage for which there is currently no satisfactory therapy. In response to this perceived need, monoclonal antibodies have been considered a direct biological modifier of the disease and a vehicle to deliver radioactive metals and other cytotoxic agents to disseminated tumor sites. J591 is a monoclonal antibody that recognizes the internal portion of PSMA, a prostatespecific membrane antigen that is regularly expressed, almost exclusively, on prostate cancer tissue. The antibody has been “humanized” to reduce immune responses to it and labeled with radioactivity. Gamma-ray-emitting labeled forms of this antibody have demonstrate a high degree of binding and β-emitting labeled forms have demostrated antitumor effects in animal models. Several of the radiolabeled forms are undergoing clinical trials in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Cancer Institute. Cancer facts and figures 2004. Atlanta, GA: American Cancer Society, 2004.

    Google Scholar 

  2. Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, et al. Prostate cancer trends 1973–1995, SEER Program. Bethesda, MD: National Cancer Institute, 1999.

    Google Scholar 

  3. Goldsmith SJ, Bander NH. Monoclonal antibody therapy. In: Khalkhali I, Maublant J, Goldsmith SJ, eds. Nuclear oncology: diagnosis and therapy. Philadelphia: Lippincott Williams & Wilkins, 2001:433–439.

    Google Scholar 

  4. Pound CR. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 2001; 3:72.

    PubMed  CAS  Google Scholar 

  5. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30: 667–677.

    Article  PubMed  CAS  Google Scholar 

  6. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7:927–935.

    PubMed  CAS  Google Scholar 

  7. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53:227–230.

    PubMed  CAS  Google Scholar 

  8. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54:1807–1811.

    PubMed  CAS  Google Scholar 

  9. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol Oncol 1995; 1:18–28.

    Google Scholar 

  10. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62:552–558.

    Article  PubMed  CAS  Google Scholar 

  11. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000; 43: 150–157.

    Article  PubMed  CAS  Google Scholar 

  12. Bostwick DB, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82:2256–2261.

    Article  PubMed  CAS  Google Scholar 

  13. Wright L Jr, Grob B, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1998; 48:326–334.

    Article  Google Scholar 

  14. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52:637–640.

    Article  PubMed  CAS  Google Scholar 

  15. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM’ protein in the LNCaP prostatic carcinoma cell line Cancer Res 1998; 58:4787–4789.

    PubMed  CAS  Google Scholar 

  16. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, et al. Prostate-specific membrane antigen: evidence for rhe existence of a second related human gene. Br J Cancer 1995; 72:583–588.

    PubMed  CAS  Google Scholar 

  17. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3:81–85.

    PubMed  CAS  Google Scholar 

  18. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998; 83:2259–2269.

    Article  PubMed  CAS  Google Scholar 

  19. Liu H, Moy P, Xia Y, Kim S, Rajasekaran AK, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57: 3629–3634.

    PubMed  CAS  Google Scholar 

  20. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostatespecific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59:3192–3198.

    PubMed  CAS  Google Scholar 

  21. Dumas F, Gala JL, Berteau F, Brasseur F, Eschwege P, Paradis V, et al. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int J Cancer 1999; 80:799–803.

    Article  PubMed  CAS  Google Scholar 

  22. Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999; 5:2674–2681.

    PubMed  CAS  Google Scholar 

  23. Troyer JK, Feng Q, Beckett ML, Wright GL Jr. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1995; 1:29–37.

    Google Scholar 

  24. Troyer JK, Beckett MI, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997; 30:232–242.

    Article  PubMed  CAS  Google Scholar 

  25. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostatespecific membrane antigen. Cancer Res 2000; 60:5237–5243.

    PubMed  CAS  Google Scholar 

  26. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navaro V, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58:4055–4060.

    PubMed  CAS  Google Scholar 

  27. Hamilton A, King S, Liu H, Moy P, Bander N, Carr F. A novel humanized antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc Am Assoc Cancer Res 1998; 39:440.

    Google Scholar 

  28. Goldsmith SJ, Kostakoglu L, Vallabhajosula S, Smith-Jones PM, Bremer S, Spangler T, et al. Evaluation of an antibody I-131 J591 in the treatment of prostate cancer. J Nucl Med 2000; 40:80P (abstract).

    Google Scholar 

  29. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled mono-clonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44:610–617.

    PubMed  CAS  Google Scholar 

  30. Smith-Jones PM, Vallabhajosula S, Navarro V, Goldsmith SJ, Bander NH. 90Y-huJ591 MAb specific to PSMA: radioimmunotherapy (RIT) studies in nude mice with prostate cancer LNCaP tumor. Eur J Nucl Med 2000; 8: 951 (abstract).

    Google Scholar 

  31. Smith-Jones PM, Navarro V, Omer SS, Bander NH, Goldsmith SJ, Vallabhajosula S. comparative antitumor effects of 90Y-DOTA-J591 and 177Lu-DOTA-J59 _in nude mice bearing LNCaP tumors. J Nucl Med 2001; 42(Suppl): 151P–152P (abstract).

    Google Scholar 

  32. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D. Vallabhajosula S, Smith-Jones P, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170:1717–1721.

    Article  PubMed  CAS  Google Scholar 

  33. Milowsky MI, Rosmarin AS, Cobham MV, et al. Anti-PSMA mAb HuJ591 specifically targets tumor vascular endothelial cells in patients with advanced solid tumor malignancies. Proc Am Soc Clin Oncol 2002; 21:19 (abstract).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University, New York, NY

    Stanley J. Goldsmith MD (Professor of Radiology and Medicine), Shankar Vallabhajosula PhD & Lale Kostakoglu MD

  2. Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY

    Matthew I. Milowsky MD & David M. Nanus MD

  3. Department of Urology, Weill Medical College of Cornell University, New York, NY

    Neil H. Bander MD

  4. Department of Medicine, Weill Medical College of Cornell University, New York, NY

    Neil H. Bander MD

Authors
  1. Stanley J. Goldsmith MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shankar Vallabhajosula PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew I. Milowsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David M. Nanus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lale Kostakoglu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Neil H. Bander MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. CuraGen Corporation, New Haven, CT

    William J. LaRochelle PhD  & Richard A. Shimkets PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Goldsmith, S.J., Vallabhajosula, S., Milowsky, M.I., Nanus, D.M., Kostakoglu, L., Bander, N.H. (2005). Development of a Radiolabeled Monoclonal Antibody to Prostate-Specific Membrane Antigen. In: LaRochelle, W.J., Shimkets, R.A. (eds) The Oncogenomics Handbook. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-893-5:617

Download citation

  • DOI: https://doi.org/10.1385/1-59259-893-5:617

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-425-8

  • Online ISBN: 978-1-59259-893-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation